Trials / Recruiting
RecruitingNCT06350318
Rituximab and Zanubrutinib in Patients With Indolent B-cell Lymphomas
A Phase 2 Open-Label, Multicenter Study of Rituximab and Zanubrutinib in Patients With Indolent B-cell Lymphomas
- Status
- Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 43 (estimated)
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of the study is to establish the safety and efficacy of zanubrutinib in combination with rituximab for people with untreated B-cell lymphomas (marginal zone lymphoma and follicular lymphomas).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Zanubrutinib | Zanubrutinib is an anti-cancer medication administered orally. |
| DRUG | Rituximab | Rituximab is a biologic medication administered intravenously or subcutaneously. |
Timeline
- Start date
- 2024-04-19
- Primary completion
- 2029-03-01
- Completion
- 2029-03-01
- First posted
- 2024-04-05
- Last updated
- 2026-02-05
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06350318. Inclusion in this directory is not an endorsement.